Welcome to the UPF Digital Repository

Comparative bioavailability study of a novel multi-day patch formulation of rivastigmine (twice weekly) with Exelon® transdermal patch (daily)- a randomized clinical trial

Show simple item record

dc.contributor.author Schurad, Bjoern
dc.contributor.author Koch, Cornelius
dc.contributor.author Schug, Barbara
dc.contributor.author Morte, Adelaida
dc.contributor.author Vaqué, Anna
dc.contributor.author Torre Fornell, Rafael de la
dc.contributor.author Iniesta, Marc
dc.date.accessioned 2023-03-22T07:14:36Z
dc.date.available 2023-03-22T07:14:36Z
dc.date.issued 2022
dc.identifier.citation Schurad B, Koch C, Schug B, Morte A, Vaqué A, De la Torre R, Iniesta M. Comparative bioavailability study of a novel multi-day patch formulation of rivastigmine (twice weekly) with Exelon® transdermal patch (daily)- a randomized clinical trial. Curr Alzheimer Res. 2022;19(7):541-53. DOI: 10.2174/1567205019666220823105059
dc.identifier.issn 1567-2050
dc.identifier.uri http://hdl.handle.net/10230/56316
dc.description.abstract Background: Rivastigmine, a reversible AChEI for symptomatic treatment of mild to moderately severe Alzheimer's dementia, is administered once daily transdermal patches, enabling an easier and continuous drug delivery. A novel multi-day (twice week) patch formulation was developed with greater convenience for patients' therapeutic management. Objective: To assess the bioequivalence under SS conditions of the multiple-day rivastigmine transdermal patch (Test Product, RID-TDS) in comparison to the once-daily Exelon® transdermal patch (Reference Product), both at a release rate of 9.5 mg/24 h. Design: Single-center, open-label, randomized, multiple-dose study in healthy male adults in a 2- period, 2-sequence-crossover design with multiple applications. Methods: Patches were applied on 11 consecutive days for Exelon® and a 4-3-4-day regimen for the multiday test patch (RID-TDS), separated by a 14-day wash-out period. The safety, local tolerability and inhibitory effect of rivastigmine on plasma BuChE activity were also evaluated. Results: 57 subjects completed the study according to the protocol. Calculated point estimates and 90% CI for all primary parameters (AUC96-264, Cmax96-264 and Cmin96-264) were within the predefined acceptance interval of 80.00-125.00%. They were 113.64% (107.33-120.33), 105.14% (98.38- 112.38) and 107.82% (97.78-118.89) respectively. Satisfactory adhesion (CI of mean adhesion above 90%) was demonstrated for RID-TDS but not for Exelon®. Conclusion: Bioequivalence was demonstrated between RID-TDS mg twice a week and Exelon® once daily in SS. Patch adhesion favored RID-TDS despite the longer dosing interval. Both products were well tolerated.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Bentham Science Publishers
dc.relation.ispartof Curr Alzheimer Res. 2022;19(7):541-53
dc.rights This is an Open Access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
dc.rights.uri https://creativecommons.org/licenses/by/4.0/legalcode
dc.title Comparative bioavailability study of a novel multi-day patch formulation of rivastigmine (twice weekly) with Exelon® transdermal patch (daily)- a randomized clinical trial
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.2174/1567205019666220823105059
dc.subject.keyword Alzheimer's disease
dc.subject.keyword Bioavailability
dc.subject.keyword Bioequivalence
dc.subject.keyword Butyrylcholinesterase
dc.subject.keyword Healthy subjects
dc.subject.keyword Pharmacokinetics
dc.subject.keyword Rivastigmine
dc.subject.keyword Transdermal patch
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking